Pharmacokinetics Grants

American Society for Clinical Pharmacology and Therapeutics Young Investigator Award

ASCPT is now accepting applications for the 2010 Young Investigator Award (YIA). The YIA award is intended to support a fellow or junior faculty member in clinical pharmacology or related field. The award includes a $35,000 grant. Deadline for applications is May 13, 2010.

The Young Investigator award is intended to support a fellow or junior faculty member in clinical pharmacology or related field who is engaged in clinical/translational research.

ASCPT broadly defines clinical research to be investigation in clinical pharmacology that is hypothesis-driven research that is focused on drug discovery and molecular research, drug development, drug action and disposition, clinical trials, regulatory sciences, therapeutics and outcomes research. Our focus is on human-based research.

The applicant must have completed a doctoral degree (MD, PharmD or PhD) at the time of grant award (July 2010) and be in a fellowship program focused on clinical pharmacology or must be within one year of the anniversary date of their faculty appointment.

• An application will be made by the applicant that describes the applicant, mentor, institution, and project. The ASCPT selection committee will critically evaluate these applications.
• An institutional commitment for a faculty appointment at time of grant submission is not required but the applicant should be working in a laboratory or clinical research setting.
• The sponsoring facility must be an academic medical institution. The primary mentor must be in the candidate’s proposed research field, must assume responsibility, and provide guidance for the research.
• Applicants must provide evidence that IRB approval is pending at the time of application.
• If the mentor is not an active ASCPT member, a supporting letter from an ASCPT member must be
included.
• Applicants should be planning an investigative career in clinical pharmacology.
• It is expected that at the time of the award, the applicant be a member of ASCPT.
• The applicant should spend at least 60-75% of his or her time in research during the award period.
• Eligible candidates may submit only one application to ASCPT per year.
• The Grant is for a one-year period, July 1, 2010 - June 30, 2011, for the total amount of $35,000.

Payments are made to the applicant’s institution in two equal installments on July 1 and January 1. The grant
is comprised of $31,000 to support the grant project, $1,500 for travel related to the project including the
ASCPT Annual Meeting and $2,500 for the institution to help defray the costs related to the administration of
the project. Disbursement of funds is contingent upon final IRB approval. If final IRB approval if not given, the award will not be granted.

• The grant funds are directed to the sponsoring institution and may provide salary support, supplies, equipment, travel, etc. necessary for pursuit of the recipient’s research project.
• At the conclusion of the grant period, a final report is required highlighting the project’s progress and summarizing the usage of funds.
• In accordance with the goals of the ASCPT to assist with the careers of young investigators, recipients are required to respond to ASCPT’s requests for information on their career progress following the active grant.

The Young Investigator Award information can be downloaded from the ASCPT web site at www.ascpt.org

Questions about the Young Investigator Award can be directed to:
Sharon J. Swan, CAE, ASCPT Executive Director
Sharon@ascpt.org or 703.836.6981

Applications are due to ASCPT by:
5:00 pm Eastern time on Thursday, May 13, 2010
Applications should be sent to:
ASCPT, 528 North Washington Street, Alexandria, VA 22314 USA

Medicinal Chemistry and Drug Metabolism/Pharmacokinetics Partners to Support Lead Discovery for Infectious Tropical Diseases

TDR is supporting innovative research on neglected disease through focused and time-limited activities. The Lead Discovery Business line of TDR (LDR) aims to facilitate the discovery of new drug leads for infectious tropical diseases through North- South networks and partnerships between public and private sectors as well as academic institutions. Through the TDRs screening activities, several confirmed hits and lead compounds have become available for further SAR exploration and progression for several TDR target diseases including schistosomiasis, onchocerciasis, filariasis, African sleeping sickness, leishmaniasis, Chagas disease, malaria and tuberculosis.

We are now seeking partners with expertise in medicinal chemistry, and DMPK to take on the optimization of available molecules evaluated through the TDR screening network. We strongly encourage applications from developing countries as we hope that work on these molecules will contribute to development of innovation in developing countries and contribute to the implementation of emerging regional innovation networks exemplified by the African Network for Drugs and Diagnostics Innovation (ANDI) and ongoing discussions for Asian and South American Networks.

Project description
Academic and research institutions, biotech and pharmaceutical companies possessing processes and capabilities in medicinal chemistry, drug metabolism and/or pharmacokinetics are encouraged to apply. Collaboration objectives are to:

* Support development of molecules through different research stage (Hit to Lead and Lead optimization)
* Work as part of the TDR drug discovery network and reporting of SAR data (chemical or biological information) to the TDR database
* Collaborate with the existing North South screening or DMPK networks of TDR for biological testing of compounds
* Participate in the development of project objectives, timelines, as well as implementation of action points identified by the TDR drug discovery committee.
* Participate in the identification of downstream partners for further compound progression and development, for example, transfer of project to the regional networks including local public private partnerships.
* Support training of fellows from disease endemic countries as an integral part of the project.

Candidate Selection
Proposals will be evaluated on the basis of the following criteria: experience and track record and experience of Principal Investigator (PI) and institution in synthetic or medicinal chemistry and DMPK, availability of basic infrastructure for synthetic/medicinal chemistry and DMPK, access to primary in vitro screens, and ability to guide post-doctoral chemists in the synthesis of analogues to explore SAR for optimization of anti-parasitic activity of compounds. Applicants are asked to develop a detailed implementation proposal covering technical and capacity building elements, budget and timelines.
Deadline

The deadline for proposals is March 31st 2010. Selected applicants will be contacted after the reviewing process.

How to apply
Please contact Ms Socorro Alias with any queries. The TDR Collaborative Research Grant form template should be used for all proposals.

On completion please submit electronically to aliass@who.int before the above deadline. Any additional documents may be submitted as appendices to this form (e.g. CVs of PI and research team, institutional letter of support).

TDR, a Special Programme for Research and Training in Tropical Diseases, is a global programme of scientific collaboration that helps coordinate, support and influence global efforts to combat a portfolio of major diseases of the poor and disadvantaged.

Established in 1975, TDR is based at and executed by the World Health Organization (WHO), and is sponsored by the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP), the World Bank and WHO.

Special Programme for Research & Training in Tropical Diseases (TDR)
World Health Organization
Avenue Appia 20
1211 Geneva 27
SWITZERLAND

Michael J. Fox Foundation for Parkinson’s Research Request for Applications for Edmond J. Safra Core Programs for PD Research

Program Goal
With the current Request for Applications (RFA), The Michael J. Fox Foundation for Parkinson’s Research
(MJFF) seeks investigators to join the effort to develop new treatments and ultimately a cure for Parkinson’s
disease (PD). The Edmond J. Safra Core Programs for PD Research, part of our annual Pipeline Programs, is a
series of three funding opportunities that seek investigator-initiated proposals focused on the following critical
points along the translational pathway to new PD therapies:

· Testing Novel Hypotheses: Funding from our Rapid Response Innovation Awards program quickly
supports high-risk, high-reward projects with little to no existing preliminary data, but potential to
significantly impact our understanding or treatment of PD.
· Validating Novel Targets: Funding from our Target Validation program supports work demonstrating
whether modulation of a novel biological target has impact in a PD-relevant animal model – an essential
early step to the development of potential targeted therapies.
· Clinical Testing of Novel Therapies: Funding from our Clinical Intervention Awards program supports
clinical testing of promising PD therapies that may significantly and fundamentally improve treatment for
people with PD.

The Pipeline Programs, including The Edmond J. Safra Core Programs for PD Research, reflect our portfolio
approach to supporting work across multiple stages of development. Applicants are encouraged to carefully
consider the specific goals of each funding program to match the state of development for their project. Each
program requires submission of a custom ‘pre-proposal’ form summarizing the novel hypothesis, new target or
clinical trial being proposed. Applicants should not submit the same idea into multiple programs; rather, choose
the stage that is right for you. MJFF staff may choose at its discretion to move a proposal into the program that it
feels is most appropriate to the apparent stage of work.

Companies interested in support for early hypothesis testing, target validation or clinical efforts are welcome to
apply to the above programs. However, companies seeking support for preclinical therapeutic development
should also consider the separately launched, industry-only Therapeutics Development Initiative. Please see the
MJFF website for more information (www.michaeljfox.org).

Pre-proposals Due

Spring: December 15, 2009 6:00pm US ET
Fall: June 1, 2010 6:00pm US ET

For additional information about this initiative, contact the Foundation at research@michaeljfox.org.

If you would like to contact the Foundation, please send an email, call toll-free at 1-800-708-7644, or contact us by regular mail at the following address:

The Michael J. Fox Foundation for Parkinson's Research
Church Street Station
P.O. Box 780
New York, NY 10008-0780

Epilepsy Research Award for Outstanding Contributions to the Pharmacology of Antiepileptic Drugs

(Deadline for submission of nominations is September 15, 2010)

The International League Against Epilepsy (ILAE) has sponsored an award of $2,000 and a Certification of Citation to be awarded by the American Society for Pharmacology and Experimental Therapeutics, for the purpose of recognizing and stimulating outstanding research leading to better clinical control of epileptic seizures. This research may include the basic screening and testing of new therapeutic agents, studies on mechanisms of action, metabolic disposition, pharmacokinetics, and clinical pharmacology studies.

The recipient will be selected by the Epilepsy Award Committee appointed by the President of ASPET, with representation of ILAE. Judgment will be based upon the significance of the candidate’s contribution to the treatment of epileptic seizures in human subjects. Selection will be free of restrictions on age, sex, nationality, institutional affiliation, or membership in scientific societies. The nominee must be actively engaged in research for which the Award is made, and primary emphasis will be placed upon work accomplished in the five-year period prior to each Award.

Nominations for the Award may be submitted by members of any recognized scientific association, domestic or foreign.

Nominations shall be submitted electronically to jane.nelson@aspet.org and shall consist of:

1. A summary describing the nominee’s major achievements.
2. Candidate’s curriculum vitae and bibliography.
3. Six of the nominee’s most significant papers, published or accepted for publication (provided as PDFs or as hyperlinks to the article). Submit each manuscript PDF as a separate attachment.

The biennial award shall be presented to the recipient at the annual meeting of ASPET. Hotel and economy airfare to the annual meeting for the recipient and his/her spouse will be provided.

Receipt date for nominations for the Epilepsy Research Award will be 5:00 pm on September 15, 2010 for an award to be presented at Experimental Biology ’11 in Washington, DC.

American Society for Pharmacology and Experimental Therapeutics
9650 Rockville Pike, Bethesda, MD 20814-3995
(301) 634-7060 info@aspet.org